€85.76
0.15% yesterday
Paris, Nov 28, 05:37 pm CET
ISIN
FR0000120578
Symbol
SAN

Sanofi Stock price

€85.76
-1.49 1.71% 1M
-6.86 7.41% 6M
-7.98 8.51% YTD
-6.34 6.88% 1Y
-2.13 2.42% 3Y
+1.55 1.84% 5Y
+1.88 2.24% 10Y
+17.94 26.46% 20Y
Paris, Closing price Fri, Nov 28 2025
-0.13 0.15%
ISIN
FR0000120578
Symbol
SAN
Industry

New AI Insights on Sanofi Insights AI Insights on Sanofi

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
€104.7b
Enterprise Value
€117.6b
Net debt
€12.8b
Cash
€8.9b
Shares outstanding
1.2b
Valuation (TTM | estimate)
P/E
7.6 | 10.8
P/S
1.6 | 2.3
EV/Sales
1.8 | 2.6
EV/FCF
-
P/B
1.4
Dividends
DPS
€3.92
Yield 1Y | 5Y
4.6% | 4.0%
Growth 1Y | 5Y
4.3% | 4.6%
Payout 1Y | 3Y
88.7% | 73.1%
Increased
25 Years
Financials (TTM | estimate)
Revenue
€66.9b | €45.3b
EBITDA
€18.1b | €14.0b
EBIT
€15.8b | €11.4b
Net Income
€13.8b | €9.6b
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
17.9% | 2.4%
EBITDA
19.2% | 33.1%
EBIT
23.5% | 31.0%
Net Income
96.3% | 73.3%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
72.3%
EBITDA
27.1% | 31.0%
EBIT
23.6%
Net
20.6% | 21.3%
Free Cash Flow
-
Financial Health
Equity Ratio
58.4%
Return on Equity
7.2%
ROCE
16.2%
ROIC
13.0%
Debt/Equity
0.3
More
EPS
€11.3
FCF per Share
-
Short interest
-
Employees
83k
Rev per Employee
€530.0k
Show more

Is Sanofi a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Sanofi Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Sanofi forecast:

23x Buy
79%
5x Hold
17%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Sanofi forecast:

Buy
79%
Hold
17%
Sell
3%

Financial data from Sanofi

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
66,905 66,905
18% 18%
100%
- Direct Costs 18,538 18,538
8% 8%
28%
48,367 48,367
22% 22%
72%
- Selling and Administrative Expenses 12,942 12,942
11% 11%
19%
- Research and Development Expense 11,330 11,330
32% 32%
17%
18,122 18,122
19% 19%
27%
- Depreciation and Amortization 2,325 2,325
4% 4%
3%
EBIT (Operating Income) EBIT 15,797 15,797
23% 23%
24%
Net Profit 13,800 13,800
96% 96%
21%

In millions EUR.

Don't miss a Thing! We will send you all news about Sanofi directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sanofi Stock News

AD HOC NEWS
13 days ago
Die erfolgreiche präklinische Entwicklung eines Biosimilars für das Milliardenmedikament Dupixent von Sanofi FR0000120578 hat die Aktien von Formycon DE000A1EWVY8 am Montagmorgen beflügelt.
AD HOC NEWS
about one month ago
Der Arzneimittelhersteller Sanofi FR0000120578 hat auch im dritten Quartal von seinem Kassenschlager Dupixent profitiert.
AD HOC NEWS
about one month ago
Das Analysehaus Jefferies hat die Einstufung für Sanofi FR0000120578 auf "Buy" mit einem Kursziel von 120 Euro belassen.
More Sanofi News

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Head office France
CEO Paul Hudson
Employees 82,878
Founded 1994
Website www.sanofi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today